Semaglutide (active ingredient) — the trial record
In STEP 1, the FDA-approved semaglutide product at 2.4 mg weekly produced ~15% placebo-adjusted weight loss over 68 weeks in non-diabetic adults with obesity. These trials studied the FDA-approved medication — not compounded formulations. Your provider determines your starting dose and titration schedule based on your assessment and response.
- → NEJM 2021 · Wilding et al., Semaglutide in Adults with Overweight or Obesity
- → JAMA 2021 · Rubino et al., STEP 4 — Effect of continued vs withdrawn treatment
